2. Signaling Pathways
  3. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  4. EGFR

EGFR

Epidermal growth factor receptor; ErbB-1; HER1

EGFR

Related Products

PDF 3.8 MB

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

EGFR Isoform Specific Products:

EGFR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168876
    AZ14240475
    		Inhibitor
    AZ14240475 is a potent, selective, and brain-penetrant inhibitor of EGFR Ex20Ins mutants, with the pIC50 of 7.6. AZ14240475 plays an important role in cancer research.
    AZ14240475
  • HY-144760
    EGFR-IN-3
    		Inducer
    EGFR-IN-3 (Compound 4c) is a potent EGFR inhibitor with an IC50 of 0.32 µM against EGFRwt-TK. EGFR-IN-3 shows cytotoxic activity against cancer cell lines and induces apoptosis.
    EGFR-IN-3
  • HY-P991239
    NM-02
    		Inhibitor
    NM-02 is an antibody targeting HER2 with an EC50 value of 1.2 nM. NM-02 binds to domains I and II of HER2-ECD, blocking HER2-related signaling pathways. NM-02 is promising for research of HER2-positive breast cancer.
    NM-02
  • HY-103437
    EGFR-IN-80
    		Inhibitor
    EGFR-IN-80 (compound 30) is an EGFR inhibitor with a pIC50 of 10.6.
    EGFR-IN-80
  • HY-172160
    HER2-IN-21
    		Inhibitor
    HER2-IN-21 (compound 657994) is a human epidermal growth factor receptor 2 (HER2) inhibitor, with an IC50 of 3.85 μM.
    HER2-IN-21
  • HY-142680
    EGFR-IN-23
    		Inhibitor
    EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC50 of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8).
    EGFR-IN-23
  • HY-146782
    EGFR-IN-49
    		Inhibitor
    EGFR-IN-49 is a potent and selective EGFR inhibitor with IC50s of 65.0 nM and 13.6 nM for EGFRT790M and EGFRT790M/L858R, respectively. EGFR-IN-49 induces late apoptosis in a dose-dependent manner.
    EGFR-IN-49
  • HY-163632
    EGFR-IN-112
    		Inhibitor
    EGFR-IN-112 (SPP10) is an EGFR kinase inhibitor which exhibits IC50s of 2.31 ± 0.3, 3.16 ± 0.8, and 4.2 ± 0.2 μM, against MCF-7, H69AR, and PC-3 cancer cells, respectively. EGFR-IN-112 also demonstrates selective cytotoxicity against cancer cells.
    EGFR-IN-112
  • HY-15772S3
    Asandeutertinib
    		Inhibitor 99.75%
    Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect.
    Asandeutertinib
  • HY-164988
    TX2-120-1
    		Degrader
    TX2-120-1 possesses the ability to bind to Her3, with an IC50 value of 56 nM for Her3. TX2-120-1 can be used for the synthesis of TX2-121-1 (HY-118998).
    TX2-120-1
  • HY-158153
    EGFR-IN-108
    		Inhibitor
    EGFR-IN-108 (Compound 12) is a selective and covalent EGFR inhibitor (pIC50: 9.4).
    EGFR-IN-108
  • HY-151882
    EGFR-IN-73
    		Inhibitor
    EGFR-IN-73 (Compound 3f) is a potent inhibitor for the most common EGFR mutation EGFR Del19 with an IC50 of 119 nM.
    EGFR-IN-73
  • HY-N2510R
    Myristicin (Standard)
    		Inhibitor
    Myristicin (Standard) is the analytical standard of Myristicin. This product is intended for research and analytical applications. Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc.
    Myristicin (Standard)
  • HY-129288
    GW837016X
    		Inhibitor
    GW837016X (NEU-391) is an orally active ErbB-2 kinase covalent inhibitor. GW837016X also is a potent antitrypanosome agent. GW837016X inhibits mitosis and cytokinesis.
    GW837016X
  • HY-162323
    EGFR-IN-106
    		Inhibitor
    EGFR-IN-106 (compound 6) is a potent EGFR inhibitor with an IC50 value of 0.2396 μM. EGFR-IN-106 shows cytotoxic and anti-inflammatory activity.
    EGFR-IN-106
  • HY-169216
    Multi-target kinase inhibitor 3
    		Inhibitor
    Multi-target kinase inhibitor 3 (compund 6i) is a multi-kinase target inhibitor with anticancer activity. Multi-target kinase inhibitor 3 inhibits EGFR, HER2, VEGFR-2, and CDK2 with IC50s of 0.063 μM, 0.054 μM, 0.119 μM, and 0.448 μM, respectively. Multi-target kinase inhibitor 3 has a good inhibitory effect on breast cancer cells MCF-7, with an IC50 of 6.10 μM.
    Multi-target kinase inhibitor 3
  • HY-162062
    EGFR WT/T790M/L858R-IN-1
    		Inhibitor
    EGFR WT/T790M/L858R-IN-1 (compound 10d) is a potent EGFR inhibitor, with IC50s of 0.097, 0.280, and 0.051?μM for EGFRWT, EGFRT790M, and EGFRL858R, respectively. EGFR WT/T790M/L858R-IN-1 can be used for the research of cancer.
    EGFR WT/T790M/L858R-IN-1
  • HY-176744
    HER2-IN-22
    		Inhibitor
    HER2-IN-22 is a potent and selective HER2 inhibitor with an IC50 of 215 μM. HER2-IN-22 possesses killing activity against various tumor cells and can induce cell apoptosis. HER2-IN-22 significantly inhibits tumor growth. HER2-IN-22 can be used in the study for tumors such as HER2+ breast cancer.
    HER2-IN-22
  • HY-150905
    EGFR ligand-2
    		Inhibitor
    EGFR ligand-2 (compound C4), a covalent EGFR ligand, is a EGFR mutant inhibitor with IC50s of 21 nM and 48 nM for EGFRL858R and EGFRL858R/T790M, respectively. EGFR ligand-2 can be used to synthesize PROTAC.
    EGFR ligand-2
  • HY-P991235
    FS102
    		Degrader
    FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a KD value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer.
    FS102
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
EGFR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.